Cancer care advocates share their thoughts on payment and delivery reform.

Test Name
Test Title, Test Company

Read biography×

Cancer care advocates share their thoughts on payment and delivery reform.

Linda House
President, Cancer Support Community

Read biography×

Linda House
President, Cancer Support Community

Follow Linda on:

Linda House has a long-standing history with the Cancer Support Community. First she served as a local, affiliate volunteer and now, as President of the headquarters office. In her current role, Linda oversees several areas of CSC including affiliate relations, strategic growth and business development, marketing and communications and the Cancer Policy Institute. Linda joined CSC after many years working in the cancer care environment, several of them being direct patient care in the acute oncology and hospice care setting.

Immediately prior to joining CSC, Linda served as Executive Director of St. Vincent Cancer Care in Indianapolis where she led a team of individuals to provide care across the full cancer continuum.  Prior to that, Linda was Senior Director of Advocacy and Professional Relations for Lilly Oncology working with patient and professional organizations on programs and broad issues related to cancer care.

Linda serves in a variety of advisory roles in the national cancer community including the National Cancer Institute’s National Council of Research Advocates, the Leadership Council for the Academy of Oncology Nurse Navigators, C-Change Together Value of Cancer Care and Workforce panels, the Patient Quality of Life Coalition Steering Committee and the patient advisory board for the Patent Resource Cancer Guide to name a few.  Linda is also an active volunteer with a number of organizations in her local community where she sits on the Board of Directors for the Indianapolis Children’s Choir among others.

 

×

Cancer care advocates share their thoughts on payment and delivery reform.

Shelly Fuld Nasso
CEO, NCCS

Read biography×

Shelly Fuld Nasso
CEO, NCCS

Follow Shelly on:

As Chief Executive Officer, Shelley has responsibility for managing all facets of NCCS, including planning and executing the public policy activities of the organization at a time of rapid and fundamental health care system change. Shelley joined NCCS in December 2012 as a consultant and in March 2013 as Senior Director of Policy before her appointment as CEO in October 2013.

Prior to joining NCCS, Shelley served in leadership roles at Susan G. Komen, where she leveraged the strength of Komen’s grassroots network to strengthen the organization’s reputation and visibility in Washington, D.C., and in state capitals. There she built productive relationships with key policymakers, agencies, coalitions and partner organizations and led a team of advocacy and volunteer leaders to influence state budgets and legislation. Under her leadership, Komen successfully secured $80 million in state funding for cancer screening and treatment for uninsured and under-insured women. She and her team also expanded the Komen grassroots advocacy program expanded from a pilot of seven affiliates to more than 100 affiliates across the country engaged in federal and state advocacy efforts.

Shelley has also served as Director of Community Philanthropy at The Dallas Foundation and held management positions at communications and technology enterprises.  She is a graduate of Rice University and holds a Master of Public Policy from the Harvard Kennedy School.

Shelley’s commitment to the work of NCCS is strongly tied to the experiences in the cancer care system of her dear friend, Dr. Brent Whitworth, a beloved physician diagnosed with stage IV cancer days before his 42nd birthday. Through Brent’s experiences, Shelley witnessed the strengths and flaws of the cancer care system and embraces the notion that policy change can directly benefit patients and caregivers going through this journey.

Shelley and her husband Michael are parents of three young boys, and her work at NCCS is her legacy for them and for Brent.

 

×

Cancer care advocates share their thoughts on payment and delivery reform.

Saira Sultan
President, Connect 4 Strategies

Read biography×

Saira Sultan
President, Connect 4 Strategies

Saira Sultan has represented corporate, nonprofit, and government interests in the legislative and regulatory health policy arena for over 20 years in Washington, DC.  She has had repeated success in designing business solutions by identifying and creating advocacy opportunities and translating them into strategic legislative and regulatory results.

Saira brings a decade of experience working with the market access, health outcomes and commercial teams in pharmaceutical companies, including Pfizer and Sanofi. Focusing in areas such as oncology, vaccines, and specialty products in sickle cell and arthritis, Saira has worked extensively with CMS, FDA, and the Hill.  Her insight and skill in working cross-functionally in a corporate environment, as well as with advocacy organizations and key trade associations will serve her clients well Saira's leadership at the Association of Community Cancer Centers allowed her to build strong relationships with the oncology community and insights into the evolution of oncology care.  She continues to work closely with many oncology organizations, identifying emerging trends that have led to repeated success in tackling coverage, coding and payment of marketed and pipeline Part B and D products.  At ACCC, the policy team under Saira's direction raised significant revenue, while improving the association's profile.  She has been an active and sought after speaker on oncology policy issues.

Complementing her 10 years in pharmaceuticals, Saira's time at Medtronic gives her an in-depth understanding of the device industry. Representing Medtronic at a time when CMS was completely revamping device reimbursement in hospital outpatient departments, gave her the opportunity to work closely with CMS and varied stakeholders. Saira successfully built a task force to ensure reimbursement for Class III devices reflecting their value to patients.

Saira brings House and Senate experience, with her work in the Ways and Means Committee, her role as senior legislative counsel for Senator Mike DeWine (R-OH), and then as Chief Counsel to one of the Senate Health Care Subcommittees. She handled all the health care issues under the Senate HELP Committee's jurisdiction, including extensive negotiations with FDA and industry on BBA 1997 and FDAMA. She spearheaded passage of the first Better Pharmaceuticals for Children.

Saira holds a JD from the University of Virginia and an undergraduate degree from the University of Maryland.

 

×

03/30/15: How can we best support initiatives that foster minority health?

Back to Top

Contributors:

      
Yanira Cruz, NHCOA President and CEO, NHCOA
Kathy Ko Chin, President & CEO, APIAHF
Amy Hinojosa, Executive Director, MANA

Join The Conversation

03/27/15: How does a strong doctor/patient relationship translate into better quality of care for the patient?

Back to Top

Contributors:

            
Edith Mitchell, M.D., Clinical Professor of Medicine and Medical Oncology, Thomas Jefferson University
Edmond Cabbabe, M.D., Chairman, Center for Patient Safety
Joshua Cohen, M.D., Neurologist, Mt. Sinai Roosevelt Hospital
Michael Ybarra, M.D., Senior Director of Alliance Development, PhRMA
Daniel Blumenthal, M.D., President, ACPM
Bill Chin, M.D., EVP, Scientific & Regulatory Affairs, PhRMA

Join The Conversation

02/11/15: What can the lessons of measles teach us about the importance of vaccines?

Back to Top

Contributors:

        
Karie Youngdahl, Director, The History of Vaccines
Anna Dragsbaek, President & CEO, Immunization Partnership
Thomas J. Berger, PH.D., Executive Director, Veterans Health Council
Roy Benaroch, MD, Adjunct Assistant Professor of Pediatrics, Pediatrician

Join The Conversation

Pages